1. Home
  2. SYY vs ALNY Comparison

SYY vs ALNY Comparison

Compare SYY & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SYY
  • ALNY
  • Stock Information
  • Founded
  • SYY 1969
  • ALNY 2002
  • Country
  • SYY United States
  • ALNY United States
  • Employees
  • SYY N/A
  • ALNY N/A
  • Industry
  • SYY Food Distributors
  • ALNY Biotechnology: Pharmaceutical Preparations
  • Sector
  • SYY Consumer Discretionary
  • ALNY Health Care
  • Exchange
  • SYY Nasdaq
  • ALNY Nasdaq
  • Market Cap
  • SYY 35.8B
  • ALNY 35.0B
  • IPO Year
  • SYY N/A
  • ALNY 2004
  • Fundamental
  • Price
  • SYY $73.22
  • ALNY $250.59
  • Analyst Decision
  • SYY Strong Buy
  • ALNY Buy
  • Analyst Count
  • SYY 13
  • ALNY 23
  • Target Price
  • SYY $84.15
  • ALNY $305.86
  • AVG Volume (30 Days)
  • SYY 4.6M
  • ALNY 687.2K
  • Earning Date
  • SYY 01-28-2025
  • ALNY 02-13-2025
  • Dividend Yield
  • SYY 2.79%
  • ALNY N/A
  • EPS Growth
  • SYY N/A
  • ALNY N/A
  • EPS
  • SYY 3.90
  • ALNY N/A
  • Revenue
  • SYY $80,570,000,000.00
  • ALNY $2,248,243,000.00
  • Revenue This Year
  • SYY $5.26
  • ALNY $22.50
  • Revenue Next Year
  • SYY $4.17
  • ALNY $30.54
  • P/E Ratio
  • SYY $18.76
  • ALNY N/A
  • Revenue Growth
  • SYY 3.94
  • ALNY 22.97
  • 52 Week Low
  • SYY $69.03
  • ALNY $141.98
  • 52 Week High
  • SYY $82.33
  • ALNY $304.39
  • Technical
  • Relative Strength Index (RSI)
  • SYY 53.75
  • ALNY 39.26
  • Support Level
  • SYY $69.78
  • ALNY $246.61
  • Resistance Level
  • SYY $72.27
  • ALNY $268.52
  • Average True Range (ATR)
  • SYY 1.28
  • ALNY 8.23
  • MACD
  • SYY 0.26
  • ALNY -3.61
  • Stochastic Oscillator
  • SYY 95.56
  • ALNY 12.20

About SYY Sysco Corporation

Sysco is the largest US foodservice distributor with 17% share of the highly fragmented $370 billion domestic market. It distributes roughly 500,000 food and nonfood products to restaurants (62% of fiscal 2024 revenue), education and government buildings (7%), travel and leisure (6%), healthcare facilities (7%), and other locations (18%) where individuals consume away-from-home meals. In fiscal 2024, 70% of the firm's revenue was derived from its US foodservice operations, while its international (18%), quick-service logistics (10%), and other (2%) segments contributed the rest.

About ALNY Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Share on Social Networks: